Genetic Downregulation of Interleukin‐6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.041814 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Larissa Ange Tchuisseu-Kwangoua und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health University of Oxford Oxford UK. Hauptthemen laut MEDLINE: Cerebral Small Vessel Diseases, Interleukin-6, Receptors, Interleukin-6. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Arteriolosclerotic cerebral small vessel disease (cSVD) is a leading cause of stroke and dementia, yet no disease‐modifying therapies exist. Anti‐inflammatory strategies targeting IL‐6 (interleukin‐6) signaling have shown efficacy in preventing atherosclerotic cardiovascular disease, but their potential in arteriolosclerotic cSVD remains unexplored. We investigated whether genetically downregulated IL‐6 signaling is associated with clinical, imaging, and pathological manifestations of arteriolosclerotic cSVD.
Methods
We applied 2‐sample Mendelian randomization using (1) 26 genetic variants near IL6R (interleukin‐6 receptor) associated with circulating C‐reactive protein levels and (2) rs2228145, a well‐characterized IL6R missense variant, as proxies of IL‐6 signaling downregulation. Outcomes included clinical (small vessel stroke, magnetic resonance imaging‐defined lacunar stroke, nonlobar intracerebral hemorrhage, vascular dementia), imaging (white matter hyperintensity volume, extensive basal ganglia perivascular space, nonlobar/mixed cerebral microbleeds), and pathological (arteriolosclerosis burden in autopsy) traits of cSVD, as well as atherosclerosis traits (ultrasound‐defined carotid plaque, large artery stroke) as positive controls. We used inverse‐variance weighting and the Wald ratio estimator for primary analyses. Mendelian randomization‐Egger regression, weighted median, and weighted mode estimators were used as sensitivity analyses.
Results
Genetically downregulated IL‐6 signaling (30% decrement in C‐reactive protein via 26 IL6R variants) was not associated with small vessel stroke (odds ratio [OR], 1.02 [95% CI, 0.95–1.10]), magnetic resonance imaging‐confirmed lacunar stroke (OR, 0.95, [95% CI, 0.81–1.11]), nonlobar intracerebral hemorrhage (OR, 1.04 [95% CI, 0.72–1.50]), or vascular dementia (OR, 1.09 [95% CI, 0.95–1.25]). Similarly, we found no significant association with cSVD imaging biomarkers or pathology‐defined arteriolosclerosis. As expected, genetically downregulated IL‐6 signaling was associated with lower odds of large artery stroke (OR, 0.79 [95% CI, 0.74–0.84]) and carotid plaque (OR, 0.88 [95% CI, 0.83–0.94]). Results were consistent across sensitivity analyses and when using the rs2228145 missense variant to proxy IL‐6 signaling downregulation.
Conclusions
Unlike atherosclerotic traits, genetically proxied IL‐6 signaling downregulation is not associated with clinical, imaging, or pathological manifestations of arteriolosclerotic cSVD. These genetic findings suggest that targeting IL‐6 signaling is unlikely to yield effects on cSVD prevention comparable with those expected for atherosclerotic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health University of Oxford Oxford UK.
- HYRICCA (Hypertension et Risque Cardiovasculaire des Camerounais) Research Team, Faculty of Medicine and Biomedical Sciences University of Yaoundé 1 Yaoundé Cameroon.
- Institute for Stroke and Dementia Research, LMU University Hospital LMU Munich Munich Germany.
- Stroke Research Group, Department of Clinical Neurosciences University of Cambridge Oxford UK.
- Wolfson Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences University of Oxford Oxford UK.
- Program in Medical and Population Genetics and Cardiovascular Disease Initiative Broad Institute of MIT and Harvard Cambridge MA USA.
ORCID-Profile: Larissa Ange Tchuisseu-Kwangoua, Murad Omarov, Hugh S Markus, Joseph Kamtchum-Tatuene, Marios K Georgakis
Zitieren
APA
Tchuisseu-Kwangoua, L. A., Omarov, M., Shatunov, A., Markus, H. S., Kamtchum-Tatuene, J., & Georgakis, M. K. (2025). Genetic Downregulation of Interleukin‐6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.041814
Vancouver
Tchuisseu-Kwangoua LA, Omarov M, Shatunov A, Markus HS, Kamtchum-Tatuene J, Georgakis MK. Genetic Downregulation of Interleukin‐6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.041814
BibTeX
@article{TchuisseuKwangoua2025,
author = {Tchuisseu-Kwangoua, Larissa Ange and Omarov, Murad and Shatunov, Alexey and Markus, Hugh S and Kamtchum-Tatuene, Joseph and Georgakis, Marios K},
title = {Genetic Downregulation of Interleukin‐6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.041814}
}
EUVIMED